AZN.ST - AstraZeneca PLC

Stockholm - Stockholm Real Time Price. Currency in SEK
644.60
+0.40 (+0.06%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close644.20
Open641.90
Bid645.10 x 0
Ask645.30 x 0
Day's Range640.50 - 650.00
52 Week Range461.30 - 650.00
Volume248,995
Avg. Volume318,950
Market Cap825.887B
Beta0.82
PE Ratio (TTM)271.98
EPS (TTM)2.37
Earnings DateN/A
Forward Dividend & Yield22.50 (3.70%)
Ex-Dividend Date2018-02-15
1y Target Est80.91
  • MarketWatch2 days ago

    U.K. stocks log record close as U.S.-China ease trade-war tensions

    U.K. stocks rose sharply on Monday, scoring a record close, as traders welcomed news over the weekend that China and the U.S. reached an agreement that eases trade tensions between the world’s two largest economies. The FTSE 100 index (^FTSE) rose 1% to end at 7,859.17, taking out its previous closing high of 7,787.97, hit last Thursday. A weaker pound tends to boost the FTSE 100, as the index’s components conduct the bulk of their business overseas and a softening in sterling lifts revenue when converted back into the U.K. currency.

  • AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
    Zacks2 days ago

    AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

    AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

  • AstraZeneca potassium drug finally approved, threatening Vifor
    Reuters2 days ago

    AstraZeneca potassium drug finally approved, threatening Vifor

    The decision by U.S. regulators to finally approve AstraZeneca's (AZN.L) much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma for $2.7 billion (2 billion pounds) in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's (VIFN.S) rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.

  • Reuters2 days ago

    AstraZeneca potassium drug finally approved, threatening Vifor

    The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma for $2.7 billion in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.

  • AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?
    Investor's Business Daily5 days ago

    AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?

    AstraZeneca dipped early Friday after the U.K.-based pharmaceutical company lagged first-quarter expectations for sales and core earnings.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks5 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript

    AZN earnings call for the period ending March 31, 2018.

  • AstraZeneca pay report rejected by 35 percent of shareholders
    Reuters5 days ago

    AstraZeneca pay report rejected by 35 percent of shareholders

    More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • AstraZeneca pay report rejected by 35 percent of shareholders
    Reuters5 days ago

    AstraZeneca pay report rejected by 35 percent of shareholders

    More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • MarketWatch5 days ago

    U.K. stocks fall from record as AstraZeneca, mining stocks decline

    FTSE 100 on track for longest weekly win run since 2005ReutersAstraZeneca shares are losing ground Friday. U.K. stocks ended lower on Friday, pulling back from the previous session’s record close, as shares of AstraZeneca declined following the heavyweight drugmaker’s earnings report, and as shares in mining companies skidded in the wake of a selloff in metals prices. The FTSE 100 index (^FTSE) dropped 0.1% to close at 7,778.79, breaking a three-day winning streak.

  • AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
    Zacks5 days ago

    AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

    AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

  • Benzinga5 days ago

    Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...

  • MarketWatch5 days ago

    Italian stocks lead Europe lower as politics spook traders

    The Stoxx Europe 600 index (^STOXX) tipped about 0.1% lower to 395.44, on track to break a three-day winning run. Italy’s FTSE MIB Index (MTAA:FTSEMIB.MI) slumped 1% to 23,564.03, as political developments in the country flustered markets. In the U.K., the FTSE 100 index (^FTSE) slipped 0.2% to 7,774.39, but was still on track for a 0.6% weekly advance.

  • AstraZeneca insists future is bright after big Crestor sales hit
    Reuters5 days ago

    AstraZeneca insists future is bright after big Crestor sales hit

    AstraZeneca's (AZN.L) first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million (663 million pounds), well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.

  • Reuters5 days ago

    AstraZeneca insists future is bright after big Crestor sales hit

    AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million, well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.

  • Associated Press5 days ago

    Astrazeneca: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Britain-based company said it had net income of 27 cents. Earnings, adjusted for non-recurring costs, came to 48 cents per share. The results topped Wall Street expectations. ...

  • The Wall Street Journal5 days ago

    [$$] AstraZeneca Profit Slides

    PLC (AZN.LN) said Friday that first-quarter profit fell 37% despite a slight rise in sales, citing divestment timing as one of the factors that hurt its overall results. The drug maker said net profit was $340 million, compared with $537 million in the first quarter of 2017 and a consensus forecast of $114.2 million, according to five analysts polled by FactSet.

  • Financial Times5 days ago

    [$$] AstraZeneca: appliance of science

    when fending off Pfizer’s advances in 2014 are looking soft. With its scientific research starting to power rapid growth, investors can afford to give the Anglo-Swedish drugs company the benefit of the doubt. Sales dropped after a faster-than-expected decline in AstraZeneca’s cholesterol-zapping drug Crestor.

  • Financial Times5 days ago

    [$$] AstraZeneca chief Pascal Soriot suffers pay revolt

    suffered a significant revolt over the pay of its chief executive Pascal Soriot on Friday, when about 35 per cent of shareholders at its annual meeting voted against its remuneration report. Mr Soriot earned £9.4m in 2017, down from £14.3m a year earlier, but ISS had complained about the level of annual bonuses he had received, suggesting that the remuneration committee should have set more stringent targets. Pointing to the sales the company is garnering from its new medicines, one insider said that Mr Soriot was being “rewarded for turning science into products”.

  • Financial Times6 days ago

    [$$] Stocks to watch: Vodafone, AstraZeneca, Glencore, Campbell Soup

    fell by their most in almost two years on Friday, down as much as 8.7 per cent after a report said the miner may face a bribery probe by the UK’s Serious Fraud Office over its ties to Israeli billionaire Dan Gertler in the Democratic Republic of Congo. The SFO is planning to seek formal approval for a probe into Glencore’s dealings in the country with its former business partner Mr Gertler, Bloomberg News reported.

  • Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?
    Zacks6 days ago

    Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?

    AstraZeneca (AZN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

  • 3 Dividend Stocks to Fund Your Nest Egg
    Motley Fool7 days ago

    3 Dividend Stocks to Fund Your Nest Egg

    A big yield worth risking and two small yields worth owning.

  • How Do Analysts See AstraZeneca PLC (LON:AZN) Performing In The Years Ahead?
    Simply Wall St.9 days ago

    How Do Analysts See AstraZeneca PLC (LON:AZN) Performing In The Years Ahead?

    AstraZeneca PLC’s (LSE:AZN) released its most recent earnings update in December 2017, which showed that the company endured a immense headwind with earnings declining by -14.23%. Investors may find itRead More...

  • Zacks Small Cap Research9 days ago

    CEMI: Q1 2018: Product Sales Off To Strong Start, And Should Steepen From Here

    As we indicated in our Q4 ’17 update (March 13, 2018: Recent Wins Mean 2018 Could Set Product Sales Record), given significant progress in development of the product pipeline (including U.S. DPP HIV/Syhp and several fever-related assays), proven success of the recently expanded (and clearly, very capable) sales team, new large contract wins (i.e. In addition to ~$6M of the Bio-Manguinhos order that remains outstanding (and which is also expected to be booked during 2018) just these two new contracts represent approximately $800k (on average) of incremental (vs. Q1 ’18) product revenue in the remaining three quarters of 2018.

  • AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
    Zacks9 days ago

    AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

    AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.